See more : Aegon N.V. (AEG) Income Statement Analysis – Financial Results
Complete financial analysis of Sorrento Therapeutics, Inc. (SRNE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Sorrento Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Poseidon Nickel Limited (PSDNF) Income Statement Analysis – Financial Results
- Maire Tecnimont S.p.A. (MAIRE.MI) Income Statement Analysis – Financial Results
- Kingfa Science & Technology (India) Limited (KINGFA.NS) Income Statement Analysis – Financial Results
- CIE Automotive India Limited (CIEINDIA.BO) Income Statement Analysis – Financial Results
- Meson Valves India Limited (MESON.BO) Income Statement Analysis – Financial Results
Sorrento Therapeutics, Inc. (SRNE)
About Sorrento Therapeutics, Inc.
Sorrento Therapeutics, Inc., a clinical stage and commercial biopharmaceutical company, develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as bispecific antibody approach; and Sofusa, a drug delivery technology that deliver biologic directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host disease. The company develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis knee pain treatment; and ZTlido, a lidocaine delivery system for the treatment of postherpetic neuralgia. It engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain condition; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for the treatment of fibromyalgia. It has collaboration with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; Celularity, Inc. for initiating Phase I/II clinical study, including up to 94 patients with COVID-19; Mount Sinai Health System to develop COVI-SHIELD, an antibody therapy targeting SARS-CoV-2 infection; and Mayo Clinic for Phase Ib pilot study using sofusa lymphatic drug delivery technology to deliver Ipilimumab in patient with melanoma. The company was founded in 2006 and is based in San Diego, California.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 62.84M | 52.90M | 39.99M | 31.43M | 21.19M | 151.86M | 8.15M | 4.59M | 3.83M | 460.15K | 583.77K | 529.18K | 682.57K | 5.41K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 33.45M | 13.03M | 9.94M | 12.24M | 10.07M | 11.03M | 3.70M | 1.95M | 2.04M | 4.44K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 29.39M | 39.87M | 30.05M | 19.20M | 11.12M | 140.83M | 4.46M | 2.64M | 1.78M | 455.71K | 583.77K | 529.18K | 682.57K | 5.41K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 46.77% | 75.37% | 75.14% | 61.07% | 52.49% | 92.74% | 54.66% | 57.52% | 46.59% | 99.04% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 221.23M | 206.92M | 111.34M | 106.88M | 76.96M | 55.53M | 42.18M | 31.34M | 23.98M | 9.02M | 3.83M | 2.57M | 1.39M | 410.17K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 63.64M | 38.33M | 24.22M | 20.13M | 9.99M | 6.32M | 1.61M | 0.00 | 0.00 | 0.00 | 0.00 | 240.63K | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -5.37M | -2.04M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 182.34M | 196.86M | 116.18M | 103.56M | 63.64M | 32.96M | 22.18M | 20.13M | 9.99M | 6.32M | 1.61M | 1.20M | 1.10M | 543.95K | 190.52K | 240.63K | 439.29K | 0.00 | 0.00 | 0.00 |
| Other Expenses | 130.14M | 4.14M | 4.05M | 3.94M | 3.01M | 2.61M | 845.00K | 1.16M | 2.35M | 804.07K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -308.03K | -763.00 | -763.00 |
| Operating Expenses | 533.70M | 407.92M | 231.57M | 214.38M | 140.60M | 88.49M | 64.35M | 52.63M | 36.32M | 16.14M | 5.44M | 3.77M | 2.49M | 954.12K | 190.52K | 240.63K | 439.29K | -308.03K | -763.00 | -763.00 |
| Cost & Expenses | 567.15M | 420.95M | 241.51M | 226.61M | 150.67M | 99.52M | 68.05M | 54.58M | 38.36M | 16.14M | 5.44M | 3.77M | 2.49M | 954.12K | 190.52K | 240.63K | 439.29K | -308.03K | -763.00 | -763.00 |
| Interest Income | 0.00 | 0.00 | 24.00K | 1.09M | 921.00K | 241.00K | 272.00K | 24.00K | 12.00K | 9.62K | 7.30K | 5.95K | 3.79K | 11.86K | 1.61K | 9.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 8.57M | 10.22M | 20.18M | 36.14M | 57.63M | 4.98M | 1.61M | 1.65M | 1.63M | 253.19K | 7.30K | 5.95K | 3.79K | 11.86K | 1.61K | 0.00 | 0.00 | 0.00 | 0.00 | 763.00 |
| Depreciation & Amortization | 13.25M | 16.32M | 14.71M | 15.04M | 9.05M | 7.08M | 2.89M | 2.37M | 3.18M | 1.29M | 293.30K | 159.22K | 23.41K | 2.76K | 3.23K | -29.99K | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -539.93M | -435.99M | -275.69M | -308.40M | -147.10M | 27.38M | -60.34M | -9.74M | -31.55M | -20.37M | -4.55M | -3.08M | -1.78M | -939.51K | -187.29K | -270.62K | -439.29K | -308.03K | -763.00 | -763.00 |
| EBITDA Ratio | -859.22% | -724.81% | -479.85% | -582.53% | -568.22% | 39.13% | -699.37% | -119.28% | -824.73% | -4,426.33% | -778.50% | -580.39% | -260.95% | -17,137.52% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -504.32M | -368.05M | -201.53M | -195.18M | -129.48M | 52.34M | -59.90M | -74.01M | -34.74M | -21.67M | -4.85M | -3.24M | -1.81M | -954.12K | -190.52K | -240.63K | -439.29K | -308.03K | -763.00 | -763.00 |
| Operating Income Ratio | -802.55% | -695.68% | -503.99% | -620.97% | -610.94% | 34.46% | -734.76% | -1,612.31% | -908.29% | -4,708.85% | -831.25% | -612.72% | -265.49% | -17,626.51% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -57.43M | -94.48M | -66.06M | -100.18M | -63.36M | -10.02M | -4.94M | 36.23M | -1.62M | -6.23M | 7.30K | 5.95K | 3.79K | 11.86K | 0.00 | -30.00K | 0.00 | -308.03K | 0.00 | 0.00 |
| Income Before Tax | -561.75M | -462.53M | -310.58M | -359.58M | -213.78M | 15.32M | -64.83M | -13.76M | -36.36M | -21.91M | -4.85M | -3.24M | -1.81M | -942.27K | 0.00 | -270.63K | 0.00 | -616.06K | 0.00 | 0.00 |
| Income Before Tax Ratio | -893.95% | -874.28% | -776.72% | -1,143.98% | -1,008.73% | 10.09% | -795.30% | -299.78% | -950.56% | -4,761.79% | -830.00% | -611.60% | -264.94% | -17,407.46% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -2.42M | -33.52M | -2.01M | -473.00K | -6.27M | -36.04M | -896.00K | 36.31M | -1.70M | 9.62K | 14.60K | 11.90K | 7.57K | 23.71K | -1.61K | -9.00 | 439.29K | -308.03K | 763.00 | 763.00 |
| Net Income | -572.84M | -429.01M | -308.57M | -359.10M | -203.54M | 9.06M | -60.92M | -45.81M | -34.66M | -21.91M | -4.85M | -3.24M | -1.81M | -942.27K | -188.90K | -270.62K | -439.29K | -308.03K | -763.00 | -763.00 |
| Net Income Ratio | -911.60% | -810.93% | -771.69% | -1,142.48% | -960.41% | 5.97% | -747.34% | -998.06% | -906.07% | -4,761.79% | -830.00% | -611.60% | -264.94% | -17,407.46% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.37 | -1.46 | -1.34 | -2.56 | -1.92 | 0.13 | -1.21 | -1.24 | -1.30 | -1.46 | -0.42 | -0.33 | -0.20 | -0.15 | -0.50 | -1.05 | -15.46 | -10.84 | -0.03 | -0.03 |
| EPS Diluted | -1.37 | -1.46 | -1.34 | -2.56 | -1.92 | 0.13 | -1.21 | -1.24 | -1.30 | -1.46 | -0.42 | -0.33 | -0.20 | -0.15 | -0.50 | -1.05 | -15.46 | -10.84 | -0.03 | -0.03 |
| Weighted Avg Shares Out | 419.32M | 294.77M | 229.82M | 140.51M | 106.15M | 69.74M | 50.36M | 36.91M | 26.68M | 15.05M | 11.41M | 9.92M | 8.83M | 6.08M | 378.02K | 257.93K | 28.41K | 28.41K | 28.41K | 28.41K |
| Weighted Avg Shares Out (Dil) | 419.32M | 294.77M | 229.82M | 140.51M | 106.15M | 70.38M | 50.36M | 36.91M | 26.68M | 15.05M | 11.41M | 9.92M | 8.83M | 6.08M | 378.02K | 257.93K | 28.41K | 28.41K | 28.41K | 28.41K |
Sorrento Releases Positive Results from a Phase 1b Study in China in COVID-19 Patients and is Ready for Pivotal Phase 3 trials with OVYDSO™ (STI-1558), an Oral Mpro Inhibitor as a Standalone Treatment for COVID-19 without the Need for Ritonavir Boosting
Biggest Penny Stocks Trading Mistakes to Avoid in 2023
Sorrento Therapeutics has Received FDA Clearance to Initiate Clinical Trials with a Next Generation mRNA (STI-1557) Vaccine Against Omicron SARS-CoV-2 Virus
Sorrento Announces Positive Phase II Results of PD-L1 Checkpoint Inhibitor IMC-001 Presented at Asian Congress of the European Society for Medical Oncology (ESMO)
Sorrento Releases Positive Topline Results from the Phase I Study Completed in Australia and Preliminary Results from a Phase Ib Study in China with STI-1558, an Oral M(pro) Inhibitor as a Standalone Treatment for COVID-19 without the Need for Ritonavir Boosting
Sorrento to Host Webcast to Discuss Newly Presented Clinical Data Demonstrating Significant Improvements in Therapeutic Outcomes in 10 of 10 Patients with Poorly Controlled Rheumatoid Arthritis
Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), Debuts on Nasdaq Under Ticker “SCLX”
Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), and Vickers Vantage Corp. I Announce the Closing of their Previously Announced Business Combination
Sorrento: Limited Potential, High Management Compensation, Complicated Lawsuits
Hurry! 7 Pitiful Stocks to Sell Before 2022 Ends
Source: https://incomestatements.info
Category: Stock Reports